Physician profile
Spencer E Ludlow
NPI 1114078797
$1,341.77
in general payments reported to CMS, 2019-2025
15 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $201 · 2021: $165 · 2022: $80.45 · 2023: $78.76 · 2024: $37.21 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $342.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $473.02 | 2019-2023 | Cequa |
| Amgen INC. | $217.31 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $114.34 | 2019-2020 | |
| Abbvie INC. | $95.32 | 2019-2023 | |
| Biotissue Holdings INC. | $71.38 | 2019 | |
| Aerie Pharmaceuticals, INC. | $69.39 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $58.33 | 2019 | |
| Allergan, INC. | $52.85 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $45.79 | 2019-2020 | |
| Alcon Vision LLC | $45.00 | 2019 | |
| Glaukos Corporation | $26.75 | 2025 | Idosetr |
| Horizon Therapeutics Plc | $23.01 | 2023 | Tepezza |
| Rxsight INC | $19.68 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Novartis Pharmaceuticals Corporation | $16.25 | 2021 | |
| New World Medical,INC. | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Ludlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.